Related Experiment Video

Updated: Jun 3, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a

R Ara1, A Pandor, J Stevens

  • 1School of Health & Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, UK. r.m.ara@sheffield.ac.uk

European Journal of Preventive Cardiology
|April 5, 2011
PubMed

Insights

High-dose statins like rosuvastatin and atorvastatin are more cost-effective for acute coronary syndrome (ACS) patients than standard simvastatin. Current policies prioritizing lower drug costs lead to suboptimal patient care and outcomes.

Area of Science:

  • Cardiovascular Medicine
  • Health Economics
  • Pharmacoeconomics

Background:

  • Evidence supports high-dose statins for reducing cardiovascular events in acute coronary syndrome (ACS).
  • Primary care trusts (PCTs) often recommend generic simvastatin 40 mg/day, potentially limiting optimal treatment.
  • This contrasts with established evidence on the benefits of higher statin doses.

Purpose of the Study:

  • To evaluate the cost-effectiveness of high-dose statins compared to standard doses in ACS patients.
  • To analyze the impact of adherence and future cost reductions on treatment value.
  • To inform optimal prescribing guidelines and healthcare policies.

Main Methods:

  • A mixed-treatment comparison of 28 randomized controlled trials (RCTs) was performed.
  • A Markov model assessed cost-effectiveness, incorporating adherence rates and projected cost changes for atorvastatin.
  • Quality-adjusted life-year (QALY) thresholds were used to determine cost-effectiveness.

Main Results:

  • A clear dose-response relationship was observed: rosuvastatin 40 mg (56% LDL reduction) > atorvastatin 80 mg (52%) > simvastatin 40 mg (37%).
  • At a £20,000/QALY threshold, high-dose rosuvastatin 40 mg, atorvastatin 80 mg, and simvastatin 40 mg were cost-effective compared to lower doses, assuming RCT adherence levels.
  • Rosuvastatin 40 mg emerged as the most cost-effective option based on net benefits, with atorvastatin 80 mg being most cost-effective if its price decreases.

Conclusions:

  • Current PCT policies focusing on minimizing drug acquisition costs lead to suboptimal patient care.
  • High-dose statin therapies offer superior clinical and economic benefits for ACS management.
  • Revising prescribing guidelines to favor evidence-based high-dose statin use is recommended.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...